secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001193125-23-271933
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA reports Q3 net loss $4.9M; THIO shows 100% DCR in second-line NSCLC, FDA IND cleared
--------------------------------------------------------------------------------

- Cash $6.1M at Sep 30, 2023 vs $10.9M at Dec 31, 2022; net loss $4.9M ($0.36/share) unchanged YoY.
- THIO-101 Phase 2 trial achieved 100% disease control rate in second-line NSCLC, exceeding standard of care 53-64%.
- FDA cleared THIO IND for U.S. enrollment in THIO-101; 49 patients dosed, enrollment pace exceeding similar trials.
- First two subjects on trial reported long-term survival of 14.6 and 12.5 months with no new anti-cancer treatment.
- R&D expenses $2.6M (up from $2.3M); G&A $2.4M (up from $1.7M) due to professional fees and investor relations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/0001193125-23-271933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000119312523271933/d578280d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-271933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer